In one paragraphArticle in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Inmaculada Navarro-Lérida *Departamento de Biología Molecular, Instituto Universitario de Biología Molecular IUBM-Universidad Autónoma de Madrid and Centro de Biología Molecular Severo Ochoa (Universidad Autónoma de Madrid-CSIC), 28049, Madrid, Spain. inmaculada.navarro@uam.es.ORCID 0000-0001-9994-8069 Raquel Huertas-Lárez *Departamento de Biología Molecular, Instituto Universitario de Biología Molecular IUBM-Universidad Autónoma de Madrid and Centro de Biología Molecular Severo Ochoa (Universidad Autónoma de Madrid-CSIC), 28049, Madrid, Spain.ORCID 0000-0001-7975-6481 Gemma Paredes-GarcíaDepartamento de Biología Molecular, Instituto Universitario de Biología Molecular IUBM-Universidad Autónoma de Madrid and Centro de Biología Molecular Severo Ochoa (Universidad Autónoma de Madrid-CSIC), 28049, Madrid, Spain.
Dafne García-MateosDepartamento de Biología Molecular, Instituto Universitario de Biología Molecular IUBM-Universidad Autónoma de Madrid and Centro de Biología Molecular Severo Ochoa (Universidad Autónoma de Madrid-CSIC), 28049, Madrid, Spain.
María Isabel Jiménez-LópezCentro Andaluz de Biología Molecular y Medicina Regenerativa, Sevilla, Spain.
Llara Prieto-FernándezInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011, Oviedo, Spain.ORCID 0000-0003-1630-890X Ania PascualSpanish Biomedical Research Network in Cancer (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.ORCID 0009-0007-5398-4962 Virginia Ávila-OcaDepartamento de Biología Molecular, Instituto Universitario de Biología Molecular IUBM-Universidad Autónoma de Madrid and Centro de Biología Molecular Severo Ochoa (Universidad Autónoma de Madrid-CSIC), 28049, Madrid, Spain.ORCID 0000-0001-8675-0037 Juan Antonio LópezCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.ORCID 0000-0002-9097-6060 Miguel A Del PozoMechanoadaptation and Caveolae Biology Laboratory, Cell and Developmental Biology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.ORCID 0000-0001-9077-391X Saúl Álvarez-TeijeiroInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011, Oviedo, Spain.ORCID 0000-0002-6845-2789 Juana María García-PedreroInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011, Oviedo, Spain.
Ramón García-EscuderoSpanish Biomedical Research Network in Cancer (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.
Federico MayorDepartamento de Biología Molecular, Instituto Universitario de Biología Molecular IUBM-Universidad Autónoma de Madrid and Centro de Biología Molecular Severo Ochoa (Universidad Autónoma de Madrid-CSIC), 28049, Madrid, Spain. fmayor@cbm.csic.es.ORCID 0000-0003-1434-8449 Catalina RibasDepartamento de Biología Molecular, Instituto Universitario de Biología Molecular IUBM-Universidad Autónoma de Madrid and Centro de Biología Molecular Severo Ochoa (Universidad Autónoma de Madrid-CSIC), 28049, Madrid, Spain. cribas@cbm.csic.es.ORCID 0000-0001-7677-6882 Funding
Comunidad de Madrid (Community of Madrid) PEJ-2023-TL-SAL-GL-26867Comunidad de Madrid (Community of Madrid) PEJ-2024-AI-SAL-GL-33271Comunidad de Madrid (Community of Madrid) S2022/BMD-7209European Commission (EC) 860229-ONCORNETGobierno del Principado de Asturias (GPA) PT23/00077MEC | Agencia Estatal de Investigación (AEI) PID2023-146735OB-I00MEC | Instituto de Salud Carlos III (ISCIII) CB16/11/00278MEC | Instituto de Salud Carlos III (ISCIII) CB16/12/00228MEC | Instituto de Salud Carlos III (ISCIII) CB16/12/00390MEC | Instituto de Salud Carlos III (ISCIII) CP23/00101MEC | Instituto de Salud Carlos III (ISCIII) PI21_00208MEC | Instituto de Salud Carlos III (ISCIII) PI22_00167MEC | Instituto de Salud Carlos III (ISCIII) PI22_00966MEC | Instituto de Salud Carlos III (ISCIII) PI24_00398Ministerio de Ciencia e Innovación (MCIN) FPU20/01588Ministerio de Ciencia e Innovación (MCIN) FPU22/00979Ministerio de Ciencia, Innovación y Universidades (MCIU) CEX2020-001041-SSpanish Agencia Estatal de Investigación CEX2021-001154-S
6 · The paper itselfAbstract
Head and neck squamous cell carcinoma is an aggressive malignancy with limited therapeutic options and poor outcomes. A key driver of tumor progression is the tumor microenvironment, particularly cancer-associated fibroblasts, which remodel the extracellular matrix and secrete pro-tumorigenic signals. Emerging evidence suggests that vesicle trafficking pathways regulate these secretory functions, though their role in HNSCC remains unclear. Building on our discovery of Gαq as an autophagy regulator, we investigated how its absence reshapes fibroblast behavior and modulates crosstalk with HNSCC cells. We demonstrate that loss of Gαq reprograms murine fibroblasts into a CAF-like phenotype through deregulated intracellular trafficking and increased ceramide accumulation. Gαq-deficient fibroblasts show increased collagen I deposition, ECM remodeling, and secretion. Their exosomes, enriched in tumor-promoting growth factor receptors, suppress Caveolin-1 in tumor cells and induce an EMT-like phenotype that fuels HNSCC growth. In co-culture and in vivo, Gαq-silenced fibroblasts form "railroad-track" structures guiding cancer cell migration and invasion. Reduced Gαq expression in human fibroblasts recapitulates these features, identifying Gαq as a key regulator of fibroblast plasticity and tumor-stroma interactions in HNSCC progression.
Indexed as
Cancer-Associated FibroblastsFibroblastsGTP-Binding Protein alpha Subunits, Gq-G11Mouth NeoplasmsAnimalsCarcinoma, Squamous CellCell Line, TumorCell MovementDisease ProgressionEpithelial-Mesenchymal TransitionExosomesExtracellular MatrixHead and Neck NeoplasmsHumansMiceTumor MicroenvironmentGTP-Binding Protein alpha Subunits, Gq-G11CAFsExosomesGαq ProteinHead and Neck Squamous Cell Carcinoma (HNSCC)Tumor Stroma
Identifiers
PMID41963732
PMCPMC13219523
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390